cefminox

Also known as cefminoxum, CMNX, (6R,7S)-7-(2-(((S)-2-Amino-2-carboxyethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid

Cefminox (INN) is a second-generation cephalosporin antibiotic.

Research

141 papers

Cefminox sodium alleviates the high-fat high-sugar-fed mice's hepatic fatty accumulation via multiple pathways.Heliyon · 2023
Severe coagulopathy caused by cefminox sodium in a liver cirrhosis patient: a case report.Infectious agents and cancer · 2022
Cefminox versus Cefoxitin in Hysterectomy Prophylaxis : Clinical Efficacy and Serum and Tissue Concentrations.Clinical drug investigation · 1997
Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats.Frontiers in pharmacology · 2018
[New antimicrobial agent series XXIV: Cefminox].The Japanese journal of antibiotics · 1987

via PubMed

Article

2 sections

Contents

Spectrum
References

Cefminox (INN) is a second-generation cephalosporin antibiotic.

==Spectrum== Cefminox is a broad-spectrum, bactericidal cephalosporin antibiotic. It is especially effective against Gram-negative and anaerobic bacteria. The following represents MIC data for a few medically significant microorganisms. Clostridioides difficile: 2 - 4 μg/ml Escherichia coli: 0.125 - 16 μg/ml Pseudomonas aeruginosa: 256 μg/ml